1-20 of 38
Keith T. Flaherty
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 583: Spatiotemporal analyses of longitudinal specimens reveal mechanisms of response and resistance to immune checkpoint blockade in metastatic melanoma

Gao Zhang, Lisa Coussens, Meenhard Herlyn, Keith T. Flaherty, Genevieve Boland, Gordon Mills
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 583.
https://doi.org/10.1158/1538-7445.AM2024-583
Published: 22 March 2024
View article titled, Abstract 583: Spatiotemporal analyses of longitudinal specimens reveal mechanisms of response and resistance to immune checkpoint blockade in metastatic melanoma
Journal Articles

Abstract 1854: Plasma proteomic biomarkers identify non-responders and reveal biological insights about the tumor microenvironment in melanoma patients after PD1 blockade

Samuel J. Wright, Deepika Yeramosu, Milan Parikh, Marijana Rucevic, Ngan Nguyen, Russell W. Jenkins, Keith T. Flaherty, Nir Hacohen, Genevieve M. Boland, Arnav Mehta
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 1854.
https://doi.org/10.1158/1538-7445.AM2024-1854
Published: 22 March 2024
View article titled, Abstract 1854: Plasma proteomic biomarkers identify non-responders and reveal biological insights about the tumor microenvironment in melanoma patients after PD1 blockade
Journal Articles

The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission

Kenneth C. Anderson, Lewis C. Cantley, Riccardo Dalla-Favera, Chi Van Dang, Luis A. Diaz, Raymond N. DuBois, Keith T. Flaherty, Philip D. Greenberg, Massimo Loda, Elaine R. Mardis, Elizabeth A. Platz, Michael N. Pollak, Robert D. Schreiber, Lillian L. Siu, Beverly A. Teicher
Journal: Cancer Research
Cancer Res (2022) 82 (21): 3861–3867.
https://doi.org/10.1158/0008-5472.CAN-22-2453
Published: 02 November 2022
View article titled, The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission
Open the PDF for The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission in another window
Journal Articles

Abstract CT160: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or with Non-V600E, Non-V600K BRAF Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol EAY131-Z1L

Vivek Subbiah, Fengmin Fengmin, Ragini Kudchadkar, Ryan J. Sullivan, Edith P. Mitchell, John J. Wright, Helen X. Chen, Robert J. Gray, Xin Victoria Wang, Lisa M. McShane, Larry V. Rubinstein, David Patton, P. Mickey Williams, Tilak K. Sundaresan, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT160.
https://doi.org/10.1158/1538-7445.AM2022-CT160
Published: 15 June 2022
View article titled, Abstract CT160: BVD-523FB (Ulixertinib) in Patients with Tumors with BRAF Fusions, or with Non-V600E, Non-V600K BRAF Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol EAY131-Z1L
Journal Articles

Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance

Jianglan Liu, Vito W. Rebecca, Andrew V. Kossenkov, Thomas Connelly, Qin Liu, Alexis Gutierrez, Min Xiao, Ling Li, Gao Zhang, Anastasia Samarkina, Delaine Zayasbazan, Jie Zhang, Chaoran Cheng, Zhi Wei, Gretchen M. Alicea, Mizuho Fukunaga-Kalabis, Clemens Krepler, Pedro Aza-Blanc, Chih-Cheng Yang, Bela Delvadia, Cynthia Tong, Ye Huang, Maya Delvadia, Alice S. Morias, Katrin Sproesser, Patricia Brafford, Joshua X. Wang, Marilda Beqiri, Rajasekharan Somasundaram, Adina Vultur, Denitsa M. Hristova, Lawrence W. Wu, Yiling Lu, Gordon B. Mills, Wei Xu, Giorgos C. Karakousis, Xiaowei Xu, Lynn M. Schuchter, Tara C. Mitchell, Ravi K. Amaravadi, Lawrence N. Kwong, Dennie T. Frederick, Genevieve M. Boland, Joseph M. Salvino, David W. Speicher, Keith T. Flaherty, Ze'ev A. Ronai, Meenhard Herlyn
Journal: Cancer Research
Cancer Res (2021) 81 (20): 5230–5241.
https://doi.org/10.1158/0008-5472.CAN-20-1496
Published: 15 October 2021
View article titled, Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance
Open the PDF for Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance in another window
Includes: Supplementary data
Journal Articles

Abstract 6670: Combined signals from tumor and immune cells predict outcomes of checkpoint inhibition in melanoma

Samuel S. Freeman, Moshe Sade-Feldman, Jaegil Kim, Chip Stewart, Arvind Ravi, Monica Arniella, Keren Yizhak, Ignaty Leshchiner, Liudmila Elagina, Oliver Spiro, Dimitri Livitz, Daniel Rosebrock, François Aguet, Jian Carrot-Zhang, Anna Gonye, Gavin Ha, Ziao Lin, Jonathan H. Chen, Dennie T. Frederick, Michal Barzily-Rokni, Marc R. Hammond, Hans Vitzthum, Shauna M. Blackmon, Yunxin J. Jiao, Donald P. Lawrence, Lyn M. Duncan, Anat Stemmer-Rachamimov, Jennifer A. Wargo, Keith T. Flaherty, Genevieve M. Boland, Ryan J. Sullivan, Matthew Meyerson, Gad Getz, Nir Hacohen
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 6670.
https://doi.org/10.1158/1538-7445.AM2020-6670
Published: 15 August 2020
View article titled, Abstract 6670: Combined signals from tumor and immune cells predict outcomes of checkpoint inhibition in melanoma
Journal Articles

Abstract CT139: NCI Molecular Analysis for Therapy Choice (NCI-MATCH EAY131) arm B: Phase II study of afatinib in patients (pts) with HER2 (ERBB2) activating mutations

Philippe L. Bedard, Shuli Li, Kari B. Wisinski, Eddy S. Yang, Sewanti A. Limaye, Edith P. Mitchell, James A. Zwiebel, Jeffrey Moscow, Robert J. Gray, Lisa M. McShane, Larry V. Rubenstein, David R. Patton, P Mickey Williams, Stanley R. Hamilton, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT139.
https://doi.org/10.1158/1538-7445.AM2019-CT139
Published: 01 July 2019
View article titled, Abstract CT139: NCI Molecular Analysis for Therapy Choice (NCI-MATCH EAY131) arm B: Phase II study of afatinib in patients (pts) with HER2 (ERBB2) activating mutations
Journal Articles

Abstract CT138: NCI-MATCH EAY131 -Z1I: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containing BRCA1 and BRCA2 mutations

Shivaani Kummar, Shuli Li, Kim Reiss, James M. Ford, Edith P. Mitchell, James A. Zwiebel, Naoko Takebe, Robert J. Gray, Lisa M. McShane, Larry V. Rubinstein, David Patton, Paul Mickey Williams, Stanley R. Hamilton, Adam Brufsky, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT138.
https://doi.org/10.1158/1538-7445.AM2019-CT138
Published: 01 July 2019
View article titled, Abstract CT138: NCI-MATCH EAY131 -Z1I: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containing <em>BRCA1</em> and <em>BRCA2</em> mutations
Journal Articles

Abstract 3013: Acquired resistance to immune checkpoint inhibition by melanoma phenotypic transformation

Arnav Mehta, David Liu, Alvin Shi, Dennie T. Frederick, Li-Lun Ho, Ana B. Larque, Benchun Miao, Rumya S. Raghavan, Tatyana Sharova, John H. Shin, Nicola Rinaldi, Ivan A. Chebib, Manolis Kellis, Eliezer Van Allen, Nir Hacohen, Keith T. Flaherty, Genevieve M. Boland, Ryan J. Sullivan
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3013.
https://doi.org/10.1158/1538-7445.AM2019-3013
Published: 01 July 2019
View article titled, Abstract 3013: Acquired resistance to immune checkpoint inhibition by melanoma phenotypic transformation
Journal Articles

Abstract LB-010: Molecular analysis for therapy choice (NCI-MATCH, EAY131) arm Z1B: Phase II trial of palbociclib for CCND1, 2 or 3 amplified tumors

Amy S. Clark, Fangxin Hong, Richard S. Finn, Angela M. DeMichele, Edith P. Mitchell, James Zweibel, Fernanda I. Arnaldez, Lisa M. McShane, Shuli Li, Robert J. Gray, Larry V. Rubenstein, David Patton, P Mickey Williams, Stanley R. Hamilton, Mehmet S. Copur, Sameer S. Kasbari, Ravneet Thind, Barbara A. Conley, Peter J. O'Dwyer, Lyndsay N. Harris, Carlos L. Arteaga, Alice P. Chen, Keith T. Flaherty
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): LB-010.
https://doi.org/10.1158/1538-7445.AM2019-LB-010
Published: 01 July 2019
View article titled, Abstract LB-010: Molecular analysis for therapy choice (NCI-MATCH, EAY131) arm Z1B: Phase II trial of palbociclib for <em>CCND1, 2 or 3</em> amplified tumors
Journal Articles

Abstract 4533: Plasma and exosome proteomic profiling for prediction of immunotherapy response and toxicity

Arnav Mehta, Gyulnara Kasumova, Alvin Shi, Marijana Rucevic, Markus Sallman-Almen, Lina Hultin Rosenberg, Emmett Sprecher, Jacqueline Ohmura, Michelle Kim, David Lieb, Xue Bai, Dennie T. Frederick, Manolis Kellis, Ryan J. Sullivan, Keith T. Flaherty, Nir Hacohen, Genevieve M. Boland
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 4533.
https://doi.org/10.1158/1538-7445.AM2019-4533
Published: 01 July 2019
View article titled, Abstract 4533: Plasma and exosome proteomic profiling for prediction of immunotherapy response and toxicity
Journal Articles

Abstract LB-144: Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy

Xin Hong, Ryan J. Sullivan, Mark Kalinich, Tanya Kwan, Shiwei Pan, Joseph A. LiCausi, John D. Milner, Linda T. Nieman, Ben S. Wittner, Uyen Ho, Tianqi Chen, Ravi Kapur, Don Lawrence, Keith T. Flaherty, Lecia V. Sequist, Sridhar Ramaswamy, David T. Miyamoto, Michael Lawrence, Anita Giobbie-Hurder, Mehmet Toner, Kurt J. Isselbacher, Shyamala Maheswaran, Daniel A. Haber
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): LB-144.
https://doi.org/10.1158/1538-7445.AM2018-LB-144
Published: 01 July 2018
View article titled, Abstract LB-144: Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy
Journal Articles

Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer

Dongmei Zhang, Gao Zhang, Xiaowen Hu, Lawrence Wu, Yi Feng, Sidan He, Youyou Zhang, Zhongyi Hu, Lu Yang, Tian Tian, Weiting Xu, Zhi Wei, Yiling Lu, Keith T. Flaherty, Xiaomin Zhong, Gordon B. Mills, Phyllis A. Gimotty, Xiaowei Xu, Meenhard Herlyn, Lin Zhang
Journal: Cancer Research
Cancer Res (2017) 77 (14): 3745–3757.
https://doi.org/10.1158/0008-5472.CAN-16-1768
Published: 13 July 2017
View article titled, Oncogenic RAS Regulates Long Noncoding RNA <em>Orilnc1</em> in Human Cancer
Open the PDF for Oncogenic RAS Regulates Long Noncoding RNA <em>Orilnc1</em> in Human Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract CT003: Activity of the ERK1/2 inhibitor ulixertinib (BVD-523) in patients with BRAF and NRAS mutant melanoma

Ryan J. Sullivan, Filip Janku, Bob T. Li, Deborah Wong, Jeffrey Sosman, Vicki Keedy, Elizabeth Buchbinder, Anthony Tolcher, Anna Varghese, David M. Hyman, Keith T. Flaherty, Antoni Ribas, Richard Carvajal, Andrea Wang-Gillam, Harriet Kluger, Manish Patel, Peter Langecker, Mary Varterasian, Dean Welsch, Jeffrey Infante
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): CT003.
https://doi.org/10.1158/1538-7445.AM2017-CT003
Published: 01 July 2017
View article titled, Abstract CT003: Activity of the ERK1/2 inhibitor ulixertinib (BVD-523) in patients with <em>BRAF</em> and <em>NRAS</em> mutant melanoma
Journal Articles

Abstract 4017: Anti-tumor activity of a BRAF inhibitor and IFNα combination in BRAF mutant melanoma

Francesco Sabbatino, Yangyang Wang, Giosuè Scognamiglio, Elvira Favoino, Steven A. Feldman, Vincenzo Villani, Keith T. Flaherty, Sjoerd Nota, Diana Giannarelli, Ester Simeone, Anna M. Anniciello, Giuseppe Palmieri, Stefano Pepe, Gerardo Botti, Paolo A. Ascierto, Cristina R. Ferrone, Soldano Ferrone
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 4017.
https://doi.org/10.1158/1538-7445.AM2016-4017
Published: 15 July 2016
View article titled, Abstract 4017: Anti-tumor activity of a BRAF inhibitor and IFNα combination in BRAF mutant melanoma
Journal Articles

Abstract 296: Targeting the melanosome: overcoming MAPK-inhibitor resistance in melanoma

April A.N. Rose, Matthew G. Annis, Dennie T. Frederick, Zhifeng Dong, Lawrence Kwong, Tibor Keller, Thomas Hawthorne, Ian R. Watson, Keith T. Flaherty, Peter M. Siegel
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 296.
https://doi.org/10.1158/1538-7445.AM2016-296
Published: 15 July 2016
View article titled, Abstract 296: Targeting the melanosome: overcoming MAPK-inhibitor resistance in melanoma
Journal Articles

Abstract 2679: Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma

Neel M. Fofaria, Dennie T. Frederick, Ryan J. Sullivan, Keith T. Flaherty, Sanjay K. Srivastava
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 2679.
https://doi.org/10.1158/1538-7445.AM2015-2679
Published: 01 August 2015
View article titled, Abstract 2679: Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma
Journal Articles

Abstract LB-239: The Hippo effector YAP promotes resistance to RAF and MEK targeted therapies

Luping Lin, Amit Sabnis, Elton Chan, Victor Olivas, Lindsay Cade, Evangelos Pazarentzos, Saurabh Asthana, Dana Neel, Jenny Jiacheng Yan, Xinyuan Lu, Luu Pham, Mingxue Wang, Niki Karachaliou, Maria G. Cao, Jose L. Manzano, Jose L. Ramirez, Jose M. Torres, Fiamma Buttitta, Charles M. Rudin, Eric A. Collisson, Alain Algazi, Eric Robinson, Iman Osman, Eva Munoz-Couselo, Javier Cortes, Dennie T. Frederick, Zachary A. Cooper, Martin McMahon, Antonio Marchetti, Rafael Rosell, Keith T. Flaherty, Jennifer A. Wargo, Trever G. Bivona
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): LB-239.
https://doi.org/10.1158/1538-7445.AM2015-LB-239
Published: 01 August 2015
View article titled, Abstract LB-239: The Hippo effector YAP promotes resistance to RAF and MEK targeted therapies
Journal Articles

Abstract P5-19-13: Clinical activity of abemaciclib, an oral cell cycle inhibitor, in metastatic breast cancer

Sara M Tolaney, Lee S Rosen, Muralidhar Beeram, Jonathan W Goldman, Leena Gandhi, Anthony W Tolcher, Kyriakos P Papadopoulos, Drew W Rasco, Scott P Myrand, Palaniappan Kulanthaivel, Joan M Andrews, Martin Frenzel, Damien M Cronier, Edward M Chan, Keith T Flaherty, Patrick Y Wen, Geoffrey I Shapiro, Amita Patnaik
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P5-19-13.
https://doi.org/10.1158/1538-7445.SABCS14-P5-19-13
Published: 01 May 2015
View article titled, Abstract P5-19-13: Clinical activity of abemaciclib, an oral cell cycle inhibitor, in metastatic breast cancer
Journal Articles

Abstract CT232: Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer

Amita Patnaik, Lee S. Rosen, Sara M. Tolaney, Anthony W. Tolcher, Jonathan W. Goldman, Leena Gandhi, Kyriakos P. Papadopoulos, Muralidhar Beeram, Drew W. Rasco, Scott P. Myrand, Palaniappan Kulanthaivel, Lily Li, Martin Frenzel, Damien M. Cronier, Edward M. Chan, Keith T. Flaherty, Patrick Y. Wen, Geoffrey I. Shapiro
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): CT232.
https://doi.org/10.1158/1538-7445.AM2014-CT232
Published: 01 October 2014
View article titled, Abstract CT232: Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer